S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NYSE:AORT

Artivion (AORT) Stock Forecast, Price & News

$15.04
-0.02 (-0.13%)
(As of 09/22/2023 ET)
Compare
Today's Range
$14.97
$15.25
50-Day Range
$14.80
$17.52
52-Week Range
$9.64
$18.00
Volume
102,260 shs
Average Volume
228,011 shs
Market Capitalization
$617.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.25

Artivion MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
54.6% Upside
$23.25 Price Target
Short Interest
Bearish
7.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
221.43%
From $0.14 to $0.45 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

689th out of 965 stocks

Surgical & Medical Instruments Industry

73rd out of 94 stocks


AORT stock logo

About Artivion (NYSE:AORT) Stock

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

AORT Price History

AORT Stock News Headlines

Financial Contrast: Surmodics (NASDAQ:SRDX) & Artivion (NYSE:AORT)
U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
Artivion Reports Second Quarter 2023 Financial Results
Earnings Preview: Artivion
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Artivion: Q1 Earnings Insights
Artivion Stock (NYSE:AORT), Dividends
Massive Insider Trade At Artivion
See More Headlines
Receive AORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter.

AORT Company Calendar

Last Earnings
8/03/2023
Today
9/23/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
1,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.25
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+54.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-19,190,000.00
Pretax Margin
-6.34%

Debt

Sales & Book Value

Annual Sales
$313.79 million
Cash Flow
$0.61 per share
Book Value
$7.05 per share

Miscellaneous

Free Float
38,331,000
Market Cap
$617.24 million
Optionable
Optionable
Beta
1.39
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. James Patrick Mackin (Age 56)
    Chairman, Pres & CEO
    Comp: $1.63M
  • Mr. David Ashley Lee CPA (Age 58)
    CPA, Exec. VP, COO & CFO
    Comp: $825.43k
  • Ms. Jean F. Holloway Esq. (Age 66)
    Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
    Comp: $636.72k
  • Mr. John E. Davis (Age 58)
    Sr. VP of Global Sales & Marketing
    Comp: $609.91k
  • Dr. Marshall S. Stanton M.D. (Age 66)
    Sr. VP of Clinical Research & Chief Medical Officer
    Comp: $615.55k
  • Ms. Amy D. Horton CPA (Age 53)
    CPA, VP & Chief Accounting Officer
  • Mr. Matthew A. Getz (Age 53)
    VP & Chief HR Officer
  • Robert C. Thomson
    VP of R&D
  • Mr. Florian Tyrs
    VP of Global Operations & GM of Hechingen













AORT Stock - Frequently Asked Questions

Should I buy or sell Artivion stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Artivion in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AORT shares.
View AORT analyst ratings
or view top-rated stocks.

What is Artivion's stock price forecast for 2023?

4 Wall Street analysts have issued 1 year price objectives for Artivion's shares. Their AORT share price forecasts range from $14.00 to $28.00. On average, they expect the company's share price to reach $23.25 in the next year. This suggests a possible upside of 54.6% from the stock's current price.
View analysts price targets for AORT
or view top-rated stocks among Wall Street analysts.

How have AORT shares performed in 2023?

Artivion's stock was trading at $12.12 at the start of the year. Since then, AORT shares have increased by 24.1% and is now trading at $15.04.
View the best growth stocks for 2023 here
.

When is Artivion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AORT earnings forecast
.

How were Artivion's earnings last quarter?

Artivion, Inc. (NYSE:AORT) issued its quarterly earnings data on Thursday, August, 3rd. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.01 by $0.05. The firm had revenue of $89.25 million for the quarter, compared to analyst estimates of $84.45 million. Artivion had a positive trailing twelve-month return on equity of 1.97% and a negative net margin of 8.66%.

What guidance has Artivion issued on next quarter's earnings?

Artivion issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $342.00 million-$350.00 million, compared to the consensus revenue estimate of $340.69 million.

What is Artivion's stock symbol?

Artivion trades on the New York Stock Exchange (NYSE) under the ticker symbol "AORT."

Who are Artivion's major shareholders?

Artivion's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (17.26%), State Street Corp (3.92%), Dimensional Fund Advisors LP (3.56%), Royce & Associates LP (2.32%), Perceptive Advisors LLC (2.27%) and Wasatch Advisors LP (1.98%). Insiders that own company stock include Amy Horton, Andrew M Green, David Ashley Lee, Dennis B Maier, James P Mackin, Matthew A Getz and Rochelle L Maney.
View institutional ownership trends
.

How do I buy shares of Artivion?

Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Artivion's stock price today?

One share of AORT stock can currently be purchased for approximately $15.04.

How much money does Artivion make?

Artivion (NYSE:AORT) has a market capitalization of $617.24 million and generates $313.79 million in revenue each year. The company earns $-19,190,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How many employees does Artivion have?

The company employs 1,300 workers across the globe.

How can I contact Artivion?

Artivion's mailing address is 1655 Roberts Blvd NW, Kennesaw, Georgia 30144-3632. The official website for the company is www.cryolife.com. The company can be reached via phone at (770) 419-3355, via email at investors@cryolife.com, or via fax at 770-426-0031.

This page (NYSE:AORT) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -